• OTS
  • December 31, 2019
SHARE
Post Views: 441

Ghadge GD, Sonobe Y, Camarena A, Drigotas C, Rigo F, Ling KK, Roos RP.

Neurobiol Dis. 2019 Dec 16;136:104702.

PubMed

Related articles

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown

April 23rd, 2021
Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

Systematic screening identifies therapeutic antisense oligonucleotides for Hutchinson-Gilford progeria syndrome

April 23rd, 2021
α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease

April 23rd, 2021
Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome

April 23rd, 2021
Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH

March 15th, 2021
Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins

Binding of phosphorothioate oligonucleotides with RNase H1 can cause conformational changes in the protein and alter the interactions of RNase H1 with other proteins

March 15th, 2021